Rebuttal From Dr Lam

DAVID C.L. LAM, Clinical testing for molecular targets for personalized treatment in lung cancer. Respirology. ,vol. 18, pp. 233- 237 ,(2013) , 10.1111/J.1440-1843.2012.02261.X

L. V. Sequist, B. A. Waltman, D. Dias-Santagata, S. Digumarthy, A. B. Turke, P. Fidias, K. Bergethon, A. T. Shaw, S. Gettinger, A. K. Cosper, S. Akhavanfard, R. S. Heist, J. Temel, J. G. Christensen, J. C. Wain, T. J. Lynch, K. Vernovsky, E. J. Mark, M. Lanuti, A. J. Iafrate, M. Mino-Kenudson, J. A. Engelman, Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors Science Translational Medicine. ,vol. 3, ,(2011) , 10.1126/SCITRANSLMED.3002003

Daniel H. Sterman, Point: Should Epidermal Growth Factor Receptor Mutations Be Routinely Tested for in Patients With Lung Cancer? Yes Chest. ,vol. 143, pp. 597- 600 ,(2013) , 10.1378/CHEST.12-2546

Pilar Garrido, Javier de Castro, Ángel Concha, Enriqueta Felip, Dolores Isla, Fernando López-Ríos, Luis Paz-Ares, José Ramírez, Julián Sanz, José Javier Gómez, None, Guidelines for biomarker testing in advanced non-small-cell lung cancer. A national consensus of the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP) Clinical & Translational Oncology. ,vol. 14, pp. 338- 349 ,(2012) , 10.1007/S12094-012-0806-2

Shan Liu, Deqiang Wang, Bo Chen, Yan Wang, Weihong Zhao, Jianqing Wu, The safety and efficacy of EGFR TKIs monotherapy versus single-agent chemotherapy using third-generation cytotoxics as the first-line treatment for patients with advanced non-small cell lung cancer and poor performance status. Lung Cancer. ,vol. 73, pp. 203- 210 ,(2011) , 10.1016/J.LUNGCAN.2010.12.006

Rafael Rosell, Enric Carcereny, Radj Gervais, Alain Vergnenegre, Bartomeu Massuti, Enriqueta Felip, Ramon Palmero, Ramon Garcia-Gomez, Cinta Pallares, Jose Miguel Sanchez, Rut Porta, Manuel Cobo, Pilar Garrido, Flavia Longo, Teresa Moran, Amelia Insa, Filippo De Marinis, Romain Corre, Isabel Bover, Alfonso Illiano, Eric Dansin, Javier De Castro, Michele Milella, Noemi Reguart, Giuseppe Altavilla, Ulpiano Jimenez, Mariano Provencio, Miguel Angel Moreno, Josefa Terrasa, Jose Muñoz-Langa, Javier Valdivia, Dolores Isla, Manuel Domine, Olivier Molinier, Julien Mazieres, Nathalie Baize, Rosario Garcia-Campelo, Gilles Robinet, Delvys Rodriguez-Abreu, Guillermo Lopez-Vivanco, Vittorio Gebbia, Lioba Ferrera-Delgado, Pierre Bombaron, Reyes Bernabe, Alessandra Bearz, Angel Artal, Enrico Cortesi, Christian Rolfo, Maria Sanchez-Ronco, Ana Drozdowskyj, Cristina Queralt, Itziar de Aguirre, Jose Luis Ramirez, Jose Javier Sanchez, Miguel Angel Molina, Miquel Taron, Luis Paz-Ares, None, Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncology. ,vol. 13, pp. 239- 246 ,(2012) , 10.1016/S1470-2045(11)70393-X

Jennifer S. Temel, Joseph A. Greer, Sonal Admane, Emily R. Gallagher, Vicki A. Jackson, Thomas J. Lynch, Inga T. Lennes, Connie M. Dahlin, William F. Pirl, Longitudinal Perceptions of Prognosis and Goals of Therapy in Patients With Metastatic Non–Small-Cell Lung Cancer: Results of a Randomized Study of Early Palliative Care Journal of Clinical Oncology. ,vol. 29, pp. 2319- 2326 ,(2011) , 10.1200/JCO.2010.32.4459

David C.L. Lam, Counterpoint: Should Epidermal Growth Factor Receptor Mutations Be Routinely Tested for in Patients With Lung Cancer? No Chest. ,vol. 143, pp. 600- 602 ,(2013) , 10.1378/CHEST.12-2548

James Chih-Hsin Yang, Jin-Yuan Shih, Wu-Chou Su, Te-Chun Hsia, Chun-Ming Tsai, Sai-Hong Ignatius Ou, Chung-Jen Yu, Gee-Chen Chang, Ching-Liang Ho, Lecia V Sequist, Arkadiusz Z Dudek, Mehdi Shahidi, Xiuyu Julie Cong, Robert M Lorence, Pan-Chyr Yang, Vincent A Miller, Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): A phase 2 trial Lancet Oncology. ,vol. 13, pp. 539- 548 ,(2012) , 10.1016/S1470-2045(12)70086-4

Tony S. Mok, Yi-Long Wu, Sumitra Thongprasert, Chih-Hsin Yang, Da-Tong Chu, Nagahiro Saijo, Patrapim Sunpaweravong, Baohui Han, Benjamin Margono, Yukito Ichinose, Yutaka Nishiwaki, Yuichiro Ohe, Jin-Ji Yang, Busyamas Chewaskulyong, Haiyi Jiang, Emma L. Duffield, Claire L. Watkins, Alison A. Armour, Masahiro Fukuoka, Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma The New England Journal of Medicine. ,vol. 361, pp. 947- 957 ,(2009) , 10.1056/NEJMOA0810699